Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07531095 |
| Title | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (DeLLphi-313) |
| Acronym | DeLLphi-313 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Amgen |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| New York University Cancer Institute | RECRUITING | New York | New York | 10016 | United States | Details |
| Baptist Cancer Center | RECRUITING | Memphis | Tennessee | 38120 | United States | Details |
| Next Virginia | RECRUITING | Fairfax | Virginia | 22031 | United States | Details |